Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).


Journal

The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545

Informations de publication

Date de publication:
Sep 2022
Historique:
revised: 07 04 2022
received: 24 02 2022
accepted: 18 04 2022
pubmed: 6 5 2022
medline: 8 9 2022
entrez: 5 5 2022
Statut: ppublish

Résumé

Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists' concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80-100%, 60-79%, and 51-59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82-89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.

Identifiants

pubmed: 35510662
doi: 10.1111/1346-8138.16422
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

837-844

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP21ck0106681h0001
Organisme : Japan Agency for Medical Research and Development
ID : JP21ck0106681h0002
Organisme : National Cancer Center Research and Development Funds
ID : 2020-J-3

Informations de copyright

© 2022 Japanese Dermatological Association.

Références

Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151:976-81.
Ito T, Inatomi Y, Nagae K, Nakano-Nakamura M, Nakahara T, Furue M, et al. Narrow-margin excision is a safe, reliable treatment for well-defined, primary pigmented basal cell carcinoma: an analysis of 288 lesions in Japan. J Eur Acad Dermatol Venereol. 2015;29:1828-31.
Cho S, Kim MH, Whang KK, Hahm JH. Clinical and histopathological characteristics of basal cell carcinoma in Korean patients. J Dermatol. 1999;26:494-501.
Takenouchi T, Takatsuka S. Long-term prognosis after surgical excision of basal cell carcinoma: a single institutional study in Japan. J Dermatol. 2013;40:696-9.
Nakamura Y, Matsushita S, Tanaka R, Saito S, Araki R, Teramoto Y, et al. 2-mm surgical margins are adequate for most basal cell carcinomas in Japanese: a retrospective multicentre study on 1000 basal cell carcinomas. J Eur Acad Dermatol Venereol. 2020;34:1991-8.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Basal Cell Skin Cancer. Version 1. 2022. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed 17 November 2021.
Mosterd K, Krekels GAM, Nieman FHM, Ostertag JU, Essers BAB, Dirksen CD, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9:1149-56.
Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987;123:340-4.
Bøgelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87:330-4.
van Iersel CA, van de Velden HV, Kusters CD, Spauwen PH, Blokx WA, Kiemeney LA, et al. Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. Br J Dermatol. 2005;153:1078-80.
Dixon AY, Lee SH, McGregor DH. Histologic features predictive of basal cell carcinoma recurrence: results of a multivariate analysis. J Cutan Pathol. 1993;20:137-42.
Jacobs GH, Rippey JJ, Altini M. Prediction of aggressive behavior in basal cell carcinoma. Cancer. 1982;49:533-7.
de Rosa G, Vetrani A, Zeppa P, Zabatta A, Barra E, Gentile R, et al. Comparative morphometric analysis of aggressive and ordinary basal cell carcinoma of the skin. Cancer. 1990;65:544-9.
Sloane JP. The value of typing basal cell carcinomas in predicting recurrence after surgical excision. Br J Dermatol. 1977;96:127-32.
Codazzi D, Van Der Velden J, Carminati M, Bruschi S, Bocchiotti MA, Di Serio C, et al. Positive compared with negative margins in a single-Centre retrospective study on 3957 consecutive excisions of basal cell carcinomas. Associated risk factors and preferred surgical management. J Plast Surg Hand Surg. 2014;48:38-43.

Auteurs

Anna Kamimura (A)

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

Yasuhiro Nakamura (Y)

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

Tatsuya Takenouchi (T)

Department of Dermatology, Niigata Cancer Center, Niigata, Japan.

Shigeto Matsushita (S)

Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

Toshikazu Omodaka (T)

Department of Dermatology, Shinshu University, Matsumoto, Japan.

Kentaro Yamamura (K)

Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

Hiroshi Uchi (H)

Department of Dermatologic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Shusuke Yoshikawa (S)

Dermatology Division, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroto Yanagisawa (H)

Department of Dermatology, Saitama Medical University, Saitama, Japan.

Takamichi Ito (T)

Department of Dermatology, Kyushu University, Fukuoka, Japan.

Yoshio Kiyohara (Y)

Dermatology Division, Shizuoka Cancer Center, Shizuoka, Japan.

Yoshio Nakamura (Y)

Department of Dermatology, Keio University, Tokyo, Japan.

Megumi Aoki (M)

Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

Shoichiro Ishizuki (S)

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Kohei Oashi (K)

Department of Dermatology, Saitama Cancer Center, Saitama, Japan.

Takuya Miyagawa (T)

Department of Dermatology, University of Tokyo, Tokyo, Japan.

Taku Maeda (T)

Department of Plastic and Reconstructive Surgery, Hokkaido University, Sapporo, Japan.

Dai Ogata (D)

Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Naohito Hatta (N)

Department of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan.

Shuichi Ohe (S)

Department of Dermatologic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Taiki Isei (T)

Department of Dermatologic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Akira Takahashi (A)

Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Yoshiyasu Umeda (Y)

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

Buntaro Yamaguchi (B)

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

Masashi Ishikawa (M)

Department of Dermatology, Saitama Cancer Center, Saitama, Japan.

Kohei Horimoto (K)

Department of Dermatology, Sapporo Medical University Hospital, Sapporo, Japan.

Yasuhiro Fujsawa (Y)

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Jiro Uehara (J)

Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Yoshitsugu Shibayama (Y)

Department of Dermatology, Fukuoka University, Fukuoka, Japan.

Yukiko Kiniwa (Y)

Department of Dermatology, Shinshu University, Matsumoto, Japan.

Yu Kawahara (Y)

Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

Taisuke Matsuya (T)

Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.

Hisashi Uhara (H)

Department of Dermatology, Sapporo Medical University Hospital, Sapporo, Japan.

Junji Kato (J)

Department of Dermatology, Sapporo Medical University Hospital, Sapporo, Japan.

Yoshiyuki Nakamura (Y)

Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Takuo Murakami (T)

Department of Dermatology, Saitama Medical University, Saitama, Japan.

Kenjiro Namikawa (K)

Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Koji Yoshino (K)

Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Takeru Funakoshi (T)

Department of Dermatology, Keio University, Tokyo, Japan.

Sumiko Takatsuka (S)

Department of Dermatology, Niigata Cancer Center, Niigata, Japan.

Yu Matsui (Y)

Department of Dermatology, Niigata Cancer Center, Niigata, Japan.

Jin Sasaki (J)

Department of Dermatology, Niigata Cancer Center, Niigata, Japan.

Hiroshi Koga (H)

Department of Dermatology, Shinshu University, Matsumoto, Japan.

Kenji Yokota (K)

Department of Dermatology, Nagoya University, Nagoya, Japan.

Takaya Komori (T)

Department of Dermatology, Kyoto University, Kyoto, Japan.

Satoshi Fukushima (S)

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Naoya Yamazaki (N)

Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH